Our Products

Product name

Dosage Form

Strength

Phase

Markets Not Available

1

Alimemazine

oral solution

7.5mg/5ml, 10mg/5ml, 30mg/5ml

Launched (UK)

UK

2

Calcium Polystyrene Sulfonate

powder for oral susp

99,934% w/w

Launched (UK)

UK

3

Carbocisteine

oral solution

250mg/5ml

750mg/5ml

Registered (EU) Launched (UK)

UK, IE

UK, MT, CY, EL, IE

4

Oxybutynin

oral solution

2.5mg/5ml, 5mg/5ml

Launched (UK)

UK

5

Oxycodone

oral solution

5mg/5ml, 10mg/ml

4mg/ml

Launched (UK)

UK, FI, SE, NO, EL

UK

6

Sodium Oxybate

oral solution

500mg/ml

Launched (UK)

NL, UK, IT, ES, DE, SE, NO, DK, EL

7

Tramadol

oral solution

50mg/5ml, 100mg/5ml

Launched (UK)

UK

8

Docusate Sodium

oral solution

12.5mg/5ml, 50mg/5ml, 100mg/5ml

Launched (UK)

UK

9

Fludrocortisone *

oral solution

0.1mg/ml

Registered (UK & EU)

UK, FR, EL

10

Methylphenidate
oral solution

10mg/5ml

Registered (UK)

UK, DE,NO,FI,DK,SE,IS

11

Ondansetron *

oral solution

4mg/5ml, 8mg/5ml

Registered (UK)

UK

12

Sodium Bicarbonate

oral solution

84mg/ml

Launched (UK)

UK

13

Tramadol +Paracetamol*
oral solution

(37.5+325)mg/5ml

Registered (EU)

14

Atropine

eye drops

1 % w/v

Registered (EU)

UK

Notes:

  • Yellow highlighted forms and strengths denote Added Value hybrid products (unique dosage forms and/or strengths).
  • Products in red denote Controlled Substances (psychotropics and/or narcotics).
  • Products marked with (*) are co-developed with HELM, who is liaised for licensing opportunities.
  • All products developed, manufactured and supplied by Labomed (except solid/semi-solid/eyedrops forms where CMOs used for manufacturing).
  • Labomed owns 16 Patent applications to EPO & PCT.
Scroll to Top